Series Name Country Name

Adults (ages 15-49) newly infected with HIV France

Adults (ages 15-49) newly infected with HIV Germany
Adults (ages 15-49) newly infected with HIV Greece
Adults (ages 15-49) newly infected with HIV Italy
Adults (ages 15-49) newly infected with HIV Netherlands
Adults (ages 15-49) newly infected with HIV Romania
Adults (ages 15-49) newly infected with HIV Spain
Adults (ages 15-49) newly infected with HIV United Kingdom
Adults (ages 15-49) newly infected with HIV United States
Adults (ages 15-49) newly infected with HIV Mexico
Adults (ages 15+) living with HIV France
Adults (ages 15+) living with HIV Germany
Adults (ages 15+) living with HIV Greece
Adults (ages 15+) living with HIV Italy
Adults (ages 15+) living with HIV Netherlands
Adults (ages 15+) living with HIV Romania
Adults (ages 15+) living with HIV Spain
Adults (ages 15+) living with HIV United Kingdom
Adults (ages 15+) living with HIV United States
Adults (ages 15+) living with HIV Mexico
Adults (ages 15+) and children (ages 0-14) newly infected with HIV France
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Germany
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Greece
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Italy
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Netherlands
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Romania
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Spain
Adults (ages 15+) and children (ages 0-14) newly infected with HIV United Kingdom
Adults (ages 15+) and children (ages 0-14) newly infected with HIV United States
Adults (ages 15+) and children (ages 0-14) newly infected with HIV Mexico
Adults (ages 15+) and children (0-14 years) living with HIV France
Adults (ages 15+) and children (0-14 years) living with HIV Germany
Adults (ages 15+) and children (0-14 years) living with HIV Greece
Adults (ages 15+) and children (0-14 years) living with HIV Italy
Adults (ages 15+) and children (0-14 years) living with HIV Netherlands
Adults (ages 15+) and children (0-14 years) living with HIV Romania
Adults (ages 15+) and children (0-14 years) living with HIV Spain
Adults (ages 15+) and children (0-14 years) living with HIV United Kingdom
Adults (ages 15+) and children (0-14 years) living with HIV United States
Adults (ages 15+) and children (0-14 years) living with HIV Mexico
AIDS estimated deaths (UNAIDS estimates) France
AIDS estimated deaths (UNAIDS estimates) Germany
AIDS estimated deaths (UNAIDS estimates) Greece
AIDS estimated deaths (UNAIDS estimates) Italy
AIDS estimated deaths (UNAIDS estimates) Netherlands
AIDS estimated deaths (UNAIDS estimates) Romania
AIDS estimated deaths (UNAIDS estimates) Spain
AIDS estimated deaths (UNAIDS estimates) United Kingdom
AIDS estimated deaths (UNAIDS estimates) United States
AIDS estimated deaths (UNAIDS estimates) Mexico
Antiretroviral therapy coverage (% of people living with HIV) France
Antiretroviral therapy coverage (% of people living with HIV) Germany
Antiretroviral therapy coverage (% of people living with HIV) Greece
Antiretroviral therapy coverage (% of people living with HIV) Italy
Antiretroviral therapy coverage (% of people living with HIV) Netherlands
Antiretroviral therapy coverage (% of people living with HIV) Romania
Antiretroviral therapy coverage (% of people living with HIV) Spain
Antiretroviral therapy coverage (% of people living with HIV) United Kingdom
Antiretroviral therapy coverage (% of people living with HIV) United States
Antiretroviral therapy coverage (% of people living with HIV) Mexico
Children orphaned by HIV/AIDS France
Children orphaned by HIV/AIDS Germany
Children orphaned by HIV/AIDS Greece
Children orphaned by HIV/AIDS Italy
Children orphaned by HIV/AIDS Netherlands
Children orphaned by HIV/AIDS Romania
Children orphaned by HIV/AIDS Spain
Children orphaned by HIV/AIDS United Kingdom
Children orphaned by HIV/AIDS United States
Children orphaned by HIV/AIDS Mexico
Children (ages 0-14) newly infected with HIV France
Children (ages 0-14) newly infected with HIV Germany
Children (ages 0-14) newly infected with HIV Greece
Children (ages 0-14) newly infected with HIV Italy
Children (ages 0-14) newly infected with HIV Netherlands
Children (ages 0-14) newly infected with HIV Romania
Children (ages 0-14) newly infected with HIV Spain
Children (ages 0-14) newly infected with HIV United Kingdom
Children (ages 0-14) newly infected with HIV United States
Children (ages 0-14) newly infected with HIV Mexico
Children (0-14) living with HIV France
Children (0-14) living with HIV Germany
Children (0-14) living with HIV Greece
Children (0-14) living with HIV Italy
Children (0-14) living with HIV Netherlands
Children (0-14) living with HIV Romania
Children (0-14) living with HIV Spain
Children (0-14) living with HIV United Kingdom
Children (0-14) living with HIV United States
Children (0-14) living with HIV Mexico
Incidence of HIV, all (per 1,000 uninfected population) France
Incidence of HIV, all (per 1,000 uninfected population) Germany
Incidence of HIV, all (per 1,000 uninfected population) Greece
Incidence of HIV, all (per 1,000 uninfected population) Italy
Incidence of HIV, all (per 1,000 uninfected population) Netherlands
Incidence of HIV, all (per 1,000 uninfected population) Romania
Incidence of HIV, all (per 1,000 uninfected population) Spain
Incidence of HIV, all (per 1,000 uninfected population) United Kingdom
Incidence of HIV, all (per 1,000 uninfected population) United States
Incidence of HIV, all (per 1,000 uninfected population) Mexico
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) France
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Germany
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Greece
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Italy
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Netherlands
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Romania
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Spain
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) United Kingdom
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) United States
Incidence of HIV, ages 50+ (per 1,000 uninfected population ages 50+) Mexico
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) France
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Germany
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Greece
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Italy
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Netherlands
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Romania
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Spain
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) United Kingdom
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) United States
Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Mexico
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) France
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Germany
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Greece
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Italy
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Netherlands
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Romania
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Spain
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) United Kingdom
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) United States
Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Mexico
Prevalence of HIV, total (% of population ages 15-49) France
Prevalence of HIV, total (% of population ages 15-49) Germany
Prevalence of HIV, total (% of population ages 15-49) Greece
Prevalence of HIV, total (% of population ages 15-49) Italy
Prevalence of HIV, total (% of population ages 15-49) Netherlands
Prevalence of HIV, total (% of population ages 15-49) Romania
Prevalence of HIV, total (% of population ages 15-49) Spain
Prevalence of HIV, total (% of population ages 15-49) United Kingdom
Prevalence of HIV, total (% of population ages 15-49) United States
Prevalence of HIV, total (% of population ages 15-49) Mexico
Prevalence of HIV, male (% ages 15-24) France
Prevalence of HIV, male (% ages 15-24) Germany
Prevalence of HIV, male (% ages 15-24) Greece
Prevalence of HIV, male (% ages 15-24) Italy
Prevalence of HIV, male (% ages 15-24) Netherlands
Prevalence of HIV, male (% ages 15-24) Romania
Prevalence of HIV, male (% ages 15-24) Spain
Prevalence of HIV, male (% ages 15-24) United Kingdom
Prevalence of HIV, male (% ages 15-24) United States
Prevalence of HIV, male (% ages 15-24) Mexico
Prevalence of HIV, female (% ages 15-24) France
Prevalence of HIV, female (% ages 15-24) Germany
Prevalence of HIV, female (% ages 15-24) Greece
Prevalence of HIV, female (% ages 15-24) Italy
Prevalence of HIV, female (% ages 15-24) Netherlands
Prevalence of HIV, female (% ages 15-24) Romania
Prevalence of HIV, female (% ages 15-24) Spain
Prevalence of HIV, female (% ages 15-24) United Kingdom
Prevalence of HIV, female (% ages 15-24) United States
Prevalence of HIV, female (% ages 15-24) Mexico
Women's share of population ages 15+ living with HIV (%) France
Women's share of population ages 15+ living with HIV (%) Germany
Women's share of population ages 15+ living with HIV (%) Greece
Women's share of population ages 15+ living with HIV (%) Italy
Women's share of population ages 15+ living with HIV (%) Netherlands
Women's share of population ages 15+ living with HIV (%) Romania
Women's share of population ages 15+ living with HIV (%) Spain
Women's share of population ages 15+ living with HIV (%) United Kingdom
Women's share of population ages 15+ living with HIV (%) United States
Women's share of population ages 15+ living with HIV (%) Mexico
Young people (ages 15-24) newly infected with HIV France
Young people (ages 15-24) newly infected with HIV Germany
Young people (ages 15-24) newly infected with HIV Greece
Young people (ages 15-24) newly infected with HIV Italy
Young people (ages 15-24) newly infected with HIV Netherlands
Young people (ages 15-24) newly infected with HIV Romania
Young people (ages 15-24) newly infected with HIV Spain
Young people (ages 15-24) newly infected with HIV United Kingdom
Young people (ages 15-24) newly infected with HIV United States
Young people (ages 15-24) newly infected with HIV Mexico

Data from database: Health Nutrition and Population Statistics

Last Updated: 09/15/2021
2011 [YR2011] 2012 [YR2012] 2013 [YR2013] 2014 [YR2014] 2015 [YR2015]
.. .. .. .. ..
2200 2400 2400 2400 2400
1000 1000 1000 1000 500
4200 4000 3900 3700 3600
1000 1000 1000 1000 1000
1000 1000 1000 1000 1000
4000 4100 4100 4000 3900
.. .. .. .. ..
33000 33000 31000 32000 32000

.. .. .. .. ..
72000 75000 77000 80000 82000
12000 12000 13000 14000 14000
110000 120000 120000 120000 130000
20000 21000 22000 22000 23000
15000 15000 16000 17000 17000
130000 130000 140000 140000 140000
.. .. .. .. ..
980000 1000000 1000000 1100000 1100000
240000 250000 260000 270000 280000
.. .. .. .. ..
2500 2800 2800 2800 2800
1100 1000 860 670 520
4600 4500 4400 4200 4100
920 850 790 720 650
840 830 820 820 810
4200 4300 43002 43003 42004
.. .. .. .. ..
39000 39000 37000 38000 38000
17000 18000 20000 19000 19000
.. .. .. .. ..
72000 75000 77000 80000 82000
12000 12000 13000 14000 14000
110000 120000 120000 120000 130000
20000 21000 22000 22000 23000
16000 16000 16000 17000 17000
130000 130000 140000 140000 140000
.. .. .. .. ..
990000 1000000 1000000 1100000 1100000
240000 250000 260000 270000 280000
.. .. .. .. ..
500 500 500 500 500
100 100 100 100 100
.. .. .. ..
100 100 100 100 100
200 200 500 500 500
870 810 760 730 720
.. .. .. .. ..
.. .. .. .. ..
 6500 6400 5800 6000 5900
.. .. .. .. ..
67 69 71 73 75
43 44 48 51 55
68 70 72 74 75
68 70 74 77 79
49 49 54 57 61
69 72 73 74 76
.. .. .. .. ..
.. .. .. .. ..
30 34 34 36 41
.. .. .. .. ..
4000 3700 3500 3200 2900
1000 1000 1000 1000 1000
.. .. .. .. ..
1000 1000 500 500 500
500 500 1000 1000 1000
17000 16000 15000 14000 12000
.. .. .. .. ..
.. .. .. .. ..
130000 140000 140000 140000 150000
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
500 500 500 500 500
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
2500 2500 2500 2400 2400
.. .. .. .. ..
0.03 0.03 0.03 0.03 0.03
0.1 0.09 0.08 0.06 0.05
0.08 0.08 0.07 0.07 0.07
0.05 0.05 0.05 0.04 0.04
0.04 0.04 0.04 0.04 0.04
0.09 0.09 0.09 0.09 0.09
.. .. .. .. ..
0.13 0.13 0.12 0.12 0.12
 0.15 0.16 0.17 0.16 0.16
.. .. .. .. ..
0.01 0.01 0.01 0.01 0.01
0.02 0.02 0.02 0.01 0.01
0.02 0.02 0.02 0.02 0.02
0.02 0.02 0.02 0.02 0.01
0.01 0.01 0.01 0.01 0.01
0.02 0.02 0.02 0.02 0.02
.. .. .. .. ..
0.06 0.06 0.05 0.06 0.06
0.06 0.07 0.07 0.07 0.06
.. .. .. .. ..
0.06 0.06 0.06 0.06 0.06
0.19 0.17 0.14 0.11 0.09
0.15 0.15 0.14 0.14 0.14
0.1 0.09 0.09 0.08 0.07
0.08 0.08 0.08 0.08 0.08
0.17 0.18 0.18 0.18 0.18
.. .. .. .. ..
0.22 0.22 0.21 0.22 0.22
0.26 0.27 0.29 0.27 0.27
.. .. .. .. ..
0.04 0.05 0.05 0.05 0.05
0.06 0.06 0.05 0.04 0.03
0.06 0.06 0.06 0.06 0.06
0.07 0.07 0.06 0.06 0.05
0.03 0.03 0.03 0.03 0.03
0.17 0.18 0.19 0.19 0.19
.. .. .. .. ..
0.22 0.2 0.19 0.18 0.17
0.17 0.18 0.19 0.19 0.18
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.1 0.2 0.2 0.2 0.2
0.3 0.3 0.3 0.3 0.3
0.2 0.2 0.2 0.2 0.2
0.1 0.1 0.1 0.1 0.1
0.4 0.4 0.4 0.4 0.4
.. .. .. .. ..
0.5 0.5 0.5 0.5 0.5
0.3 0.3 0.3 0.3 0.3
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.2 0.2 0.2 0.2
.. .. .. .. ..
0.2 0.2 0.2 0.2 0.1
 0.1 0.1 0.1 0.1 0.1
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
.. .. .. ..
19.8 19.8 19.7 19.7 19.6
16.1 16 16 16 16
28.1 28.1 28.1 28.2 28.2
17.9 17.9 18 18 18.1
47 46.3 45.4 44.1 43
18.2 18.2 18.1 18.1 18.1
.. .. .. .. ..
23.5 23.3 23.1 22.9 22.7
18.3 18.3 18.5 18.7 18.8
.. .. .. .. ..
500 500 500 500 500
100 100 100 100 100
500 500 500 500 500
200 200 200 200 200
100 100 100 100 100
1000 1000 1000 1000 1000
.. .. .. .. ..
9100 8700 8000 7600 7300
3700 4000 4200 4100 4000
2016 [YR2016] 2017 [YR2017] 2018 [YR2018] 2019 [YR2019] 2020 [YR2020]
.. .. .. .. ..
2400 2200 2200 2300 2200
500 500 500 1000 1000
3500 3300 2900 2400 2200
500 500 500 500 500
1000 1000 1000 1000 1000
3800 3700 3600 3400 3200
.. .. .. .. ..
32000 31000 30000 29000 ..

.. .. .. .. ..
84000 87000 89000 91000 93000
14000 15000 15000 16000 17000
130000 130000 130000 140000 140000
23000 23000 24000 24000 24000
18000 18000 19000 19000 19000
140000 150000 150000 150000 150000
.. .. .. .. ..
1100000 1100000 1200000 1200000 ..
290000 300000 320000 330000 340000
.. .. .. .. ..
2900 2600 2700 2700 2600
500 500 550 730 980
4000 3800 3300 2800 2500
570 500 500 500 500
810 800 790 780 770
4100 4000 3900 3700 3500
.. .. .. .. ..
38000 37000 36000 35000 ..
19000 19000 20000 20000 20000
.. .. .. .. ..
84000 87000 89000 91000 93000
14000 15000 15000 16000 17000
130000 130000 130000 140000 140000
23000 23000 24000 24000 24000
18000 18000 19000 19000 19000
140000 150000 150000 150000 150000
.. .. .. .. ..
1100000 1100000 1200000 1200000 ..
300000 310000 320000 340000 340000
.. .. .. .. ..
500 500 500 500 500
100 100 100 100 100
.. .. .. .. ..
100 100 100 100 100
200 200 500 500 500
710 730 730 740 740
.. .. .. .. ..
.. .. .. .. ..
 5000 4500 5000 4400 4300
.. .. .. .. ..
77 80 81 85 86
60 62 66 67 67
77 82 87 87 91
81 83 85 86 88
62 64 65 67 66
83 84 85 85 85
.. .. .. .. ..
.. .. .. .. ..
44 46 51 52 55
.. .. .. .. ..
2700 2400 2200 2000 1800
1000 1000 1000 1000 1000
.. .. .. .. ..
500 500 500 500 500
1000 1000 1000 1100 1100
11000 9900 8700 7600 6600
.. .. .. .. ..
.. .. .. .. ..
150000 140000 140000 140000 140000
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
500 500 500 500 500
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
.. .. .. .. ..
2300 2300 2300 2300 2300
.. .. .. .. ..
0.03 0.03 0.03 0.03 0.03
0.04 0.04 0.05 0.07 0.09
0.07 0.06 0.06 0.05 0.04
0.03 0.03 0.02 0.02 0.02
0.04 0.04 0.04 0.04 0.04
0.09 0.09 0.08 0.08 0.08
.. .. .. .. ..
0.12 0.12 0.11 0.11 ..
 0.16 0.16 0.16 0.16 0.16
.. .. .. .. ..
0.01 0.01 0.01 0.01 0.01
0.01 0.01 0.01 0.02 0.02
0.02 0.02 0.02 0.01 0.01
0.01 0.01 0.01 0.01 0.01
0.01 0.01 0.01 0.01 0.01
0.02 0.02 0.02 0.02 0.01
.. .. .. .. ..
0.05 0.05 0.05 0.05 ..
0.07 0.07 0.07 0.07 0.07
.. .. .. .. ..
0.07 0.06 0.06 0.06 0.06
0.08 0.08 0.1 0.13 0.18
0.14 0.13 0.12 0.1 0.09
0.06 0.05 0.04 0.03 0.03
0.08 0.08 0.08 0.08 0.08
0.18 0.18 0.17 0.17 0.16
.. .. .. .. ..
0.22 0.21 0.21 0.2 ..
0.27 0.27 0.27 0.27 0.27
.. .. .. .. ..
0.05 0.04 0.04 0.04 0.04
0.03 0.03 0.03 0.05 0.06
0.05 0.05 0.05 0.04 0.04
0.04 0.04 0.03 0.02 0.02
0.03 0.03 0.03 0.03 0.03
0.19 0.19 0.19 0.18 0.17
.. .. .. .. ..
0.16 0.16 0.15 0.15 ..
0.19 0.19 0.19 0.19 0.18
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.2 0.2 0.2 0.2 0.2
0.3 0.3 0.3 0.2 0.2
0.2 0.2 0.2 0.2 0.2
0.1 0.1 0.1 0.1 0.1
0.4 0.4 0.4 0.4 0.4
.. .. .. .. ..
0.4 0.4 0.4 0.4 ..
0.3 0.3 0.3 0.4 0.4
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.2 0.2 0.2 0.2 0.2
.. .. .. .. ..
0.1 0.1 0.1 0.1 ..
 0.1 0.1 0.1 0.1 0.1
.. .. .. .. ..
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
.. .. .. .. ..
0.1 0.1 0.1 0.1 ..
0.1 0.1 0.1 0.1 0.1
.. .. .. .. ..
19.6 19.6 19.6 19.6 19.6
16 16 16 16 16
28.2 28.3 28.4 28.5 28.6
18.1 18.2 18.2 18.3 18.3
42 41.2 40.4 39.5 38.7
18 17.9 17.8 17.7 17.7
.. .. .. .. ..
22.6 22.5 22.4 22.3 ..
18.9 19.2 18.9 18.8 17.7
.. .. .. .. ..
500 500 500 500 500
100 100 100 100 100
500 500 500 500 500
100 100 100 100 100
100 100 100 100 100
1000 1000 1000 1000 1000
.. .. .. .. ..
6800 6500 6400 6100 ..
4100 4100 4100 4100 4000
Capitale tari
Paris
Berlin
Atena
Roma
Amsterdan Minima Maxima
Bucuresti
Madrid Indicator 1 500 33000
Londra Indicator 2 12000 1200000
Washinton Indicator 3 12000 39000
Indicator 4 12000 1200000
Indicator 5 100 6500
Indicator 6 30 91
Indicator 7 500 150000
Inicator 8 500 500
Indicator 9 2300 2500
Indicator 10 0.02 0.17
Indicator 11 0.01 0.07
Indicator 12 0.03 0.29
Indicator 13 0.02 0.22
Indicator 14 0.1 0.5
Indicator 15 0.1 0.2
Indicator 16 0.1 0.1
Indicator 17 16 47
Indicator 18 100 9100
Total 36321807 36321806.71

Column1 Column2 Column3

0% 0% 0%
147000% 152000% 157000%
24000% 25000% 27000%
230000% 240000% 240000%
41000% 43000% 44000%
32000% 32000% 33000%
260000% 270000% 280000%
0% 0% 0%
1990000% 2000000% 2100000%
490000% 510000% 530000%
0% 0% 0%
1000% 1000% 1000%
200% 200% 200%
0% 0% 0%
200% 200% 200%
Media Mediana

5842.028986 2200
211658.2278 93000
8918.550725 2700
212189.8734 48000
1202.333333 500
67.2 69.5
26356.66667 1450
500 500
2380 2350
0.074936709 0.07
0.025696203 0.02
0.139367089 0.13
0.094303797 0.06
0.253164557 0.2
0.116455696 0.1
0.1 0.1
23.0278481 19.2
1650.632911 500
36321806.71 36321806.71

Column4 Column5 Column6 Column7 Column8 Column9 Column10 Column11

0% 0% 0% 0% 0% 0% 0% 0%
162000% 166000% 171000% 176000% 180000% 184000% 93000% 0%
28000% 28000% 29000% 30000% 31000% 33000% 17000% 0%
250000% 260000% 260000% 260000% 270000% 280000% 140000% 0%
45000% 46000% 46000% 47000% 48000% 48000% 24000% 0%
34000% 35000% 36000% 37000% 38000% 38000% 19000% 0%
280000% 280000% 290000% 300000% 300000% 300000% 150000% 0%
0% 0% 0% 0% 0% 0% 0% 0%
2200000% 2200000% 2200000% 2300000% 2400000% 1200000% 0% 0%
550000% 580000% 610000% 630000% 660000% 680000% 340000% 0%
0% 0% 0% 0% 0% 0% 0% 0%
1000% 1000% 1000% 1000% 1000% 1000% 500% 0%
200% 200% 200% 200% 200% 200% 100% 0%
0% 0% 0% 0% 0% 0% 0% 0%
200% 200% 200% 200% 200% 200% 100% 0%
Column12 Column13 Column14 Column15 Column16
0% 0% 0% 0% 0%
0% 2990% 3090% 3190% 3280%
1470% 490% 520% 550% 560%
240% 4700% 4800% 4900% 5100%
2300% 840% 870% 890% 910%
410% 640% 650% 670% 690%
320% 5300% 5500% 5600% 5600%
2600% 0% 0% 0% 0%
0% 39900% 41000% 43000% 44000%
19900% 10000% 10400% 10800% 11300%
4900% 0% 0% 0% 0%
0% 20% 20% 20% 20%
10% 4% 4% 4% 4%
2% 0% 0% 0% 0%
0% 4% 4% 4% 4%
Column1 Column2
Code License Type
SH.HIV.INCD CC BY-4.0
SH.DYN.AIDS CC BY-4.0
SH.HIV.INCD.TL CC BY-4.0
SH.HIV.TOTL CC BY-4.0
SH.DYN.AIDS.DH CC BY-4.0
SH.HIV.ARTC.ZS CC BY-4.0
SH.HIV.ORPH CC BY-4.0
SH.HIV.INCD.14 CC BY-4.0
SH.HIV.0014 CC BY-4.0
SH.HIV.INCD.TL.P3 CC BY-4.0
SH.HIV.INCD.50.P3
SH.HIV.INCD.ZS CC BY-4.0
SH.HIV.INCD.YG.P3 CC BY-4.0
SH.DYN.AIDS.ZS CC BY-4.0
SH.HIV.1524.MA.ZSCC BY-4.0
SH.HIV.1524.FE.ZS CC BY-4.0
SH.DYN.AIDS.FE.ZS CC BY-4.0
SH.HIV.INCD.YG CC BY-4.0
Column3
Indicator Name
Adults (ages 15-49) newly infected with HIV
Adults (ages 15+) living with HIV
Adults (ages 15+) and children (ages 0-14) newly infected with
Adults (ages 15+) and children (0-14 years) living with HIV
AIDS estimated deaths (UNAIDS estimates)
Antiretroviral therapy coverage (% of people living with HIV)
Children orphaned by HIV/AIDS
Children (ages 0-14) newly infected with HIV
Children (0-14) living with HIV
Incidence of HIV, all (per 1,000 uninfected population)
Incidence of HIV, ages 50+ (per 1,000 uninfected population ag
Incidence of HIV, ages 15-49 (per 1,000 uninfected population
Incidence of HIV, ages 15-24 (per 1,000 uninfected population
Prevalence of HIV, total (% of population ages 15-49)
Prevalence of HIV, male (% ages 15-24)
Prevalence of HIV, female (% ages 15-24)
Women's share of population ages 15+ living with HIV (%)
Young people (ages 15-24) newly infected with HIV
Long definition
Number of adults (ages 15-49) newly infected with HIV.
Adults living with HIV refers to the number of people ages 15-4
Number of adults (ages 15+) and children (ages 0-14) newly inf
Adults and children living with HIV refers to the number of peo
AIDS deaths are the estimated number of adults and children w
Antiretroviral therapy coverage indicates the percentage of all
Number of children orphaned by HIV/AIDS is the estimated numbe
Number of children (ages 0-14) newly infected with HIV.
Children living with HIV refers to the number of children ages
Number of new HIV infections among uninfected populations exp
Number of new HIV infections among uninfected populations age
Number of new HIV infections among uninfected populations age
Number of new HIV infections among uninfected populations age
Prevalence of HIV refers to the percentage of people ages 15-4
Prevalence of HIV, male is the percentage of males who are infe
Prevalence of HIV, female is the percentage of females who are
Prevalence of HIV is the percentage of people who are infected
Number of young people (ages 15-24) newly infected with HIV.
Source
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
UNAIDS estimates.
Topic
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
Periodicity
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Annual
Aggregation method

Weighted average

Weighted average
Weighted average
Weighted average
Weighted average
Weighted average
Weighted average
Weighted average
Weighted average
Statistical concept and methodology

Antiretroviral therapy has led to huge reductions in death and suffering of people with advanced HIV infection.

Data on incidence of HIV are from the Joint United Nations Pro
Data on incidence of HIV are from the Joint United Nations Pro
Data on incidence of HIV are from the Joint United Nations Pro
Data on incidence of HIV are from the Joint United Nations Pro
Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions
Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions
Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions
Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions
 Development relevance
Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t

Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t

death and suffering of people with advanced HIV infection.

Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t

Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t
Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t
Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t
Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t
ramme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries
ramme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries
ramme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries
ramme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries
Despite the existence of effective medications and treatment, HIV/AIDS is still a leading cause of death and public health t
 Limitations and exceptions
treatment, HIV/AIDS is still a leading cause of death and public health thr

treatment, HIV/AIDS is still a leading cause of death and public health thr

The limited availability of data on health status is a major constraint in assessing the health situation in developing countri

treatment, HIV/AIDS is still a leading cause of death and public health thr

treatment, HIV/AIDS is still a leading cause of death and public health thr
treatment, HIV/AIDS is still a leading cause of death and public health thr
treatment, HIV/AIDS is still a leading cause of death and public health thr
treatment, HIV/AIDS is still a leading cause of death and public health thr
The limited availability of data on health status is a major constraint in assessing the health situation in developing countri
The limited availability of data on health status is a major con
The limited availability of data on health status is a major con
The limited availability of data on health status is a major constraint in assessing the health situation in developing countri
treatment, HIV/AIDS is still a leading cause of death and public health thr
 General comments Column1 Column2 Column3
This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health c

This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

This is an age-disaggregated indicator for Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].
This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].
This is an age-disaggregated indicator for Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].
major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health c
In many developing countries most new infections occur in young adults, with young women being especially vulnerable.
In many developing countries most new infections occur in young adults, with young women especially vulnerable.
major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health c
This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].
 Column4 Column5 Column6 Column7 Column8 Column9 Column10 Column11
gs/metadata/].

gs/metadata/].

g for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliab

gs/metadata/].

stats.un.org/sdgs/metadata/].

stats.un.org/sdgs/metadata/].
g for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliab
men being especially vulnerable.
men especially vulnerable.
g for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliab
gs/metadata/].
 Column12 Column13 Column14 Column15 Column16 Column17 Column18

iseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or repor

iseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or repor

iseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or repor
 Column19 Column20 Column21 Column22 Column23 Column24 Column25

ty and willingness to collect or report information.

ty and willingness to collect or report information.

ty and willingness to collect or report information.

Column26 Column27 Column28 Column29 Column30 Column31 Column32